Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 1311
TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316365(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(1-piperidylm...)
Affinity DataKi:  1nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316345( cis-N-tert-Butyl-2-[2-(3-chlorophenyl)-4-oxo-6-[3...)
Affinity DataKi: <1nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316327(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(thiomorpholi...)
Affinity DataKi: <1nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316341(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-methyl-1-piperi...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316322(cis-2-[2-(3-chlorophenyl)-4-oxo-6-[3-(1-piperidylm...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316342( cis-2-[2-(3-Chlorophenyl)-6-[3-[(3-hydroxy-8-azab...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316344(cis-2-[2-(3-Chlorophenyl)-6-[3-(1,4-oxazepan-4-ylm...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316349(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-fluoro-1-piperi...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316350(cis-2-[2-(3-Chlorophenyl)-6-[3-(6-oxa-2-azaspiro[3...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316352( cis-2-[2-(3-Chlorophenyl)-6-[3-[[(3R)-3-hydroxy-1...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316353(cis-2-[2-(3-Chlorophenyl)-6-[3-[[(3R)-3-methylpyrr...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316355(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-hydroxy-4-methy...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316356( cis-2-[2-(3-Chlorophenyl)-6-[3-[ [(3S)-3-hydroxy-...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316357(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-[[4-(trifluor...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316358(cis-2-[2-(3-Chlorophenyl)-6-[3-[(3-fluoro-1-piperi...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316359(cis-2-[2-(3-Chlorophenyl)-6-[3-[(3-hydroxyazetidin...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316360(cis-2-[2-(3-Chlorophenyl)-6-[3-(7-oxa-2-azaspiro[3...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316361( cis-2-[2-(3-Chlorophenyl)-6-[3-[[(2S,6R)-2,6-dime...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316363(cis-2-[2-(3-Chlorophenyl)-6-[3-[[(3R)-3-methylmorp...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316364( cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(1-piperidyl...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316340( cis-2-[6-[3-(Azepan-1-ylmethyl)cyclobutyl]-2-(3-c...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316338(cis-2-[2-(3-Chlorophenyl)-6-[3-[(3-fluoroazetidin-...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316337(cis-2-[2-(3-Chlorophenyl)-6-[3-(3,6-dihydro-2H-pyr...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316335(cis-2-[2-(3-Chlorophenyl)-6-[3-[ [(3S)-3-fluoropyr...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316329(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-methoxy-1-piper...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316333(cis-2-[2-(3-Chlorophenyl)-6-[3-[(3-cyano-1-piperid...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316328(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(pyrrolidin-1...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316332(cis-2-[2-(3-Chlorophenyl)-6-[3-(morpholinomethyl)c...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316331(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4,4-difluoro-1-pi...)
Affinity DataKi:  5.5nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316321( 2-(2-(3-Chlorophenyl)-4-oxo-6-(3-(piperidin-1-ylm...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316323(trans-2-[2-(3-chlorophenyl)-4-oxo-6-[3-(1-piperidy...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316324(2-[2-(3-Chlorophenyl)-4-oxo-6-[2-[2-(1-piperidyl)e...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316362( cis-2-[2-(3-Chlorophenyl)-6-[3-[(2,6-dimethylmorp...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316325(2-[2-(3-Chlorophenyl)-4-oxo-6-[2-(1-piperidylmethy...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316326(Cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-cyano-1-piperid...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316328(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(pyrrolidin-1...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316354( cis-2-[2-(3-Chlorophenyl)-6-[3-[(3-methoxyazetidi...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316334(cis-2-[2-(3-Chlorophenyl)-6-[3-(diethylaminomethyl...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316351(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-hydroxy-1-piper...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316336( cis-2-[2-(3-Chlorophenyl)-6-[3-(dimethylaminometh...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316348(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(1-piperidylm...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316347( cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(1-piperidyl...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316346(cis-2-[2-(3-Chlorophenyl)-4-oxo-6-[3-(1-piperidylm...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316343(cis-2-[2-(3-Chlorophenyl)-6-[3-[[(3S)-3-methylpyrr...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent

TargetVasopressin V1a receptor(Human)
Abbvie Deutschland

US Patent
LigandPNGBDBM316339(cis-2-[2-(3-Chlorophenyl)-6-[3-[(4-ethoxy-1-piperi...)
Affinity DataKi:  55nMAssay Description:The binding assay was carried out by the method based on that of Tahara et al. (Tahara A et al., Brit. J. Pharmacol. 125, 1463-1470 (1998)).The incub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/8/2019
Entry Details
Go to US Patent